CRI
Carter's, Inc.
CRI has the edge over NKE overall, supported by stronger fundamentals and stronger valuation.
NKE
NIKE, Inc.
NKE has slightly lower modeled downside risk, despite its lower overall score.
CRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CRI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
CRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.6x | $33.87 | — |
| Cheap | 8.6x | $51.89 | +53% |
| Forward | 10x | $33.87 | — |
| Fair | 12x | $74.79 | +121% |
| Expensive | 18x | $107 | +215% |
Historical ranges are pointers, not guarantees.
CRI has the edge over NKE in the historical PE scenario, which offers more potential upside but is not a forecast.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE's PE is in its cheap range at 18x. On analysts' estimates for next year's earnings, today's price would be 30x, in its fair range.
CRI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
CRI has the edge over NKE on the outlook, with more favorable earnings and revenue expectations.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
CRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.24 | -46% |
| Q3 2026 | $6.03 | +145% |
| Q2 2026 | $5.35 | +42% |
| Q1 2026 | $2.49 | -45% |
| Q4 2025 | $2.53 | -51% |
| Q3 2025 | $2.46 | -61% |
| Q2 2025 | $3.76 | -42% |
| Q1 2025 | $4.51 | -29% |
| Q4 2024 | $5.12 | -18% |
CRI earned $6.03 per share over the past year, up 145% from the year before.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
CRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $752.5M | -0.7% |
| Q2 2026 | $615.5M | +5.2% |
| Q1 2026 | $681.1M | +8.1% |
| Q4 2025 | $925.5M | +7.6% |
| Q3 2025 | $757.8M | -0.1% |
| Q2 2025 | $585.3M | +3.7% |
| Q1 2025 | $629.8M | -4.8% |
| Q4 2024 | $859.7M | +0.2% |
CRI has the edge over NKE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +3.6 points |
| Q2 2026 | 23% | +22 points |
| Q1 2026 | 4.2% | 0 points |
| Q4 2025 | 9.2% | -0.5 points |
| Q3 2025 | 3.8% | -6.3 points |
| Q2 2025 | 0.7% | -6.3 points |
| Q1 2025 | 4.1% | -4.2 points |
| Q4 2024 | 9.7% | -6.2 points |
CRI's operating margin was 7.4% last quarter, up 3.6 points from the same quarter a year ago.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE has the edge over CRI on profitability, with a higher operating margin.
CRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$117.4M | +$26.7M |
| Q2 2026 | $190M | +688% |
| Q1 2026 | -$543K | +$58.4M |
| Q4 2025 | $247.6M | -8.6% |
| Q3 2025 | -$144.1M | -$48.4M |
| Q2 2025 | $24.1M | -77% |
| Q1 2025 | -$59M | -$21.4M |
| Q4 2024 | $270.9M | -11% |
CRI has the edge over NKE on cash flow, with more consistent year-over-year improvement.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
CRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +36.1K shares |
| 1 year | +0.5% | +192K shares |
| 3 years | -2.2% | -806K shares |
| 5 years | -18% | -7.8M shares |
| Available history | -20% | -9.1M shares |
CRI has 36M diluted shares, up 0.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16.7M |
| Q2 2024 | $24.8M |
| Q1 2024 | $9M |
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has the edge over CRI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
CRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.3x | Very low |
CRI's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE has the edge over CRI on leverage, with a lower net debt burden relative to earnings.
CRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 29.2 | Neutral |
CRI's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
CRI PE vs Consumer Cyclical Sector
| Metric | CRI | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 18x | 69% below |
| PE % | 1 | 47 | 46 pts below |
CRI has the edge over NKE on valuation relative to its sector.
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE is trading at 18x earnings, in line with the Consumer Cyclical sector's median of 18x.
CRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.1 | 5.5% above |
| 20 week MA | $34.7 | 2.5% below |
| 50 week MA | $35.7 | 5% below |
| 100 week MA | $36.0 | 6% below |
| 200 week MA | $52.7 | 36% below |
CRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 36% below its 200-week average.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
CRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.1 | $95.0 | -14% |
| 2021 | $95.0 | $98.7 | +3.9% |
| 2022 | $98.7 | $73.4 | -26% |
| 2023 | $73.4 | $74.9 | +2.1% |
| 2024 | $74.9 | $54.4 | -27% |
| 2025 | $54.4 | $31.7 | -42% |
| 2026 YTD | $31.7 | $33.9 | +6.9% |
CRI has the edge over NKE on returns for 2026, with the stronger performance.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has finished four years in a row lower, and it's down 38% so far in 2026.